TuHURA Biosciences (NASDAQ:HURA) Stock Price Up 2.8% – What’s Next?

TuHURA Biosciences, Inc. (NASDAQ:HURA) shares shot up 2.8% during mid-day trading on Thursday . The company traded as high as $2.66 and last traded at $2.59. 397,707 shares changed hands during trading, a decline of 21% from the average session volume of 500,792 shares. The stock had previously closed at $2.52.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on HURA. Rodman & Renshaw began coverage on shares of TuHURA Biosciences in a report on Wednesday, April 15th. They issued a “buy” rating on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Tuesday, April 21st. Wall Street Zen cut shares of TuHURA Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, May 31st. Citigroup started coverage on shares of TuHURA Biosciences in a report on Monday, April 27th. They set an “outperform” rating for the company. Finally, Citizens Jmp initiated coverage on TuHURA Biosciences in a research report on Monday, April 27th. They set a “market outperform” rating and a $9.00 price objective for the company. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $9.00.

TuHURA Biosciences Stock Down 14.1%

The business’s fifty day moving average is $2.39 and its two-hundred day moving average is $1.65. The stock has a market capitalization of $141.69 million, a PE ratio of -3.65 and a beta of 0.01.

TuHURA Biosciences (NASDAQ:HURA) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). Sell-side analysts expect that TuHURA Biosciences, Inc. will post -0.56 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new position in shares of TuHURA Biosciences in the 3rd quarter worth approximately $26,000. Wells Fargo & Company MN boosted its stake in TuHURA Biosciences by 109.0% during the fourth quarter. Wells Fargo & Company MN now owns 38,208 shares of the company’s stock worth $29,000 after buying an additional 19,931 shares during the period. Geode Capital Management LLC increased its position in TuHURA Biosciences by 6.4% during the fourth quarter. Geode Capital Management LLC now owns 662,481 shares of the company’s stock valued at $501,000 after acquiring an additional 39,710 shares during the last quarter. Jane Street Group LLC bought a new position in TuHURA Biosciences during the first quarter valued at $69,000. Finally, Bank of America Corp DE purchased a new stake in shares of TuHURA Biosciences in the fourth quarter valued at $59,000. Hedge funds and other institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.